Jingping Liu

Dr. Jingping Liu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Theranostics
Verified
Journal Article
Open access
MZMeng Zhao
Meng Zhao
YWYizhuo Wang
Yizhuo Wang
LLLing Li
Ling Li
SLShuyun Liu
Shuyun Liu
CWChengshi Wang
Chengshi Wang
JLJingping Liu
Jingping Liu
Aims: Ischemia-reperfusion injury (IRI)-induced acute kidney injury (IRI-AKI) is characterized by elevated levels of reactive oxygen species (ROS), mitochondrial dysfunction, and inflammation, but the potential link among these features remains unclear. In this study, we aimed to investigate the specific role of mitochondrial ROS (mtROS) in initiating mitochondrial DNA (mtDNA) damage and inflammation during IRI-AKI.

28 December 2020 in ACS Nano
Verified
Journal Article
Closed access
MZMeng Zhao
Meng Zhao
SLShuyun Liu
Shuyun Liu
CWChengshi Wang
Chengshi Wang
YWYizhuo Wang
Yizhuo Wang
MWMeihua Wan
Meihua Wan
JLJingping Liu
Jingping Liu

28 October 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YWYizhuo Wang
Yizhuo Wang
MZMeng Zhao
Meng Zhao
SLShuyun Liu
Shuyun Liu
JGJun Guo
Jun Guo
YLYanrong Lu
Yanrong Lu
JLJingping Liu
Jingping Liu
Macrophages (Mφ) are primary innate immune cells that exhibit diverse functions in response to different pathogens or stimuli, and they are extensively involved in the pathology of various diseases. Extracellular vesicles (EVs) are small vesicles released by live cells. As vital messengers, macrophage-derived EVs (Mφ-EVs) can transfer multiple types of bioactive molecules from macrophages to recipient cells, modulating the biological function of recipient cells. In recent years, Mφ-EVs have emerged as vital mediators not only in the pathology of multiple diseases such as inflammatory diseases, fibrosis and cancers, but also as mediators of beneficial effects in immunoregulation, cancer therapy, infectious defense, and tissue repair. Although many investigations have been performed to explore the diverse functions of Mφ-EVs in disease pathology and intervention, few studies have comprehensively summarized their detailed biological roles as currently understood. In this review, we briefly introduced an overview of macrophage and EV biology, and primarily focusing on current findings and future perspectives with respect to the pathological and therapeutic effects of Mφ-EVs in various diseases.

14 August 2019 in Clinical Science
Verified
Journal Article
Open access
PDF file
YYYujia Yuan
Yujia Yuan
YCYounan Chen
Younan Chen
TPTianqing Peng
Tianqing Peng
LLLan Li
Lan Li
WZWuzheng Zhu
Wuzheng Zhu
YLYanrong Lu
Yanrong Lu
Macrophage polarization toward the M1 phenotype and its subsequent inflammatory response have been implicated in the progression of diabetic complications. Despite adverse consequences of autophagy impairment on macrophage inflammation, the regulation of macrophage autophagy under hyperglycemic conditions is incompletely understood. Here, we report that the autophagy–lysosome system and mitochondrial function are impaired in streptozotocin (STZ)-induced diabetic mice and high glucose (HG)-stimulated RAW 264.7 cells. Mitochondrial dysfunction promotes reactive oxygen species (ROS) production and blocks autophagic flux by impairing lysosome function in macrophages under hyperglycemic conditions. Conversely, inhibition of mitochondrial ROS by Mito-TEMPO prevents HG-induced M1 macrophage polarization, and its effect is offset by blocking autophagic flux. The role of mitochondrial ROS in lysosome dysfunction and M1 macrophage polarization is also demonstrated in mitochondrial complex I defective RAW 264.7 cells induced by silencing NADH:ubiquinone oxidoreductase subunit-S4 (Ndufs4). These findings prove that mitochondrial ROS plays a key role in promoting macrophage polarization to inflammatory phenotype by impairing autophagy–lysosome system, which might provide clue to a novel treatment for diabetic complications.

1 December 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
YZYijie Zhou
Yijie Zhou
SLShuyun Liu
Shuyun Liu
MZMeng Zhao
Meng Zhao
CWChengshi Wang
Chengshi Wang
LLLing Li
Ling Li
JLJingping Liu
Jingping Liu

21 October 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
QHQian Hu
Qian Hu
JYJiaqi Yao
Jiaqi Yao
XWXiajia Wu
Xiajia Wu
JLJuan Li
Juan Li
GLGuixiang Li
Guixiang Li
MWMeihua Wan
Meihua Wan
Severe acute pancreatitis-associated acute lung injury (SAP-ALI) is a serious disease associated with high mortality. Emodin has been applied to alleviate SAP-ALI; however, the mechanism remains unclear. We report that the therapeutic role of emodin in attenuating SAP-ALI is partly dependent on an exosomal mechanism. SAP rats had increased levels of plasma exosomes with altered protein contents compared to the sham rats. These infused plasma exosomes tended to accumulate in the lungs and promoted the hyper-activation of alveolar macrophages and inflammatory damage. Conversely, emodin treatment decreased the plasma/pancreatic exosome levels in the SAP rats. Emodin-primed exosomes showed less pro-inflammatory effects in alveolar macrophages and lung tissues than SAP exosomes. In detail, emodin-primed exosomes suppressed the NF-κB pathway to reduce the activation of alveolar macrophage and ameliorate lung inflammation by regulating PPARγ pathway, while these effects were amplified/abolished by PPARγ agonist/antagonist. Blockage of pancreatic acinar cell exosome biogenesis also exhibited suppression of alveolar macrophage activation and reduction of lung inflammation. This study suggests a vital role of exosomes in participating inflammation-associated organ-injury, and indicates emodin can attenuate SAP-ALI by reducing the pancreatic exosome-mediated alveolar macrophage activation.